Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 2/20 | 0.48 |
| ▸ | GRM5 | P41594 | 1/20 | 0.45 |
| ▸ | CHUK | O15111 | 1/20 | 0.45 |
| ▸ | TXNRD1 | Q16881 | 1/20 | 0.45 |
| ▸ | NOX4 | Q9NPH5 | 1/20 | 0.45 |
| ▸ | STAT3 | P40763 | 8/20 | 0.42 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.36 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.35 |
| ▸ | PPARD | Q03181 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | XBP1 | P17861 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7153588 | 0.85 | CASP3 (0.53) | CASP3CHUKTXNRD1NOX4STAT3 | |
| SCHEMBL7048686 | 0.84 | CASP3 (0.52) | CASP3GRM5CHUKTXNRD1NOX4 | |
| SCHEMBL7158427 | 0.81 | CASP3 (0.49) | CASP3GRM5CHUKTXNRD1NOX4 | |
| SCHEMBL7051693 | 0.80 | CHUK (0.68) | CASP3GRM5CHUKTXNRD1NOX4 | |
| SCHEMBL7188135 | 0.79 | CASP3 (0.42) | CASP3GRM5CHUKTXNRD1NOX4 | |
| SCHEMBL6449089 | 0.77 | CASP3 (0.49) | CASP3GRM5STAT3MAPTPKM | |
| SCHEMBL7157911 | 0.74 | CASP3 (0.44) | CASP3GRM5CHUKTXNRD1NOX4 | |
| SCHEMBL6454367 | 0.72 | NPC1 (0.52) | CASP3GRM5MAPTPKM | |
| SCHEMBL7044304 | 0.71 | CASP3 (0.50) | CASP3GRM5CHUKTXNRD1NOX4 | |
| SCHEMBL7156609 | 0.71 | CASP3 (0.47) | CASP3CHUKTXNRD1NOX4STAT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050075375-A1 | Heterocyclic compounds for treating hepatitis C virus | ANADYS PHARMACEUTICALS, INC. (US) | 2005-04-07 | — | — | US | disclosed |
| WO-2004110351-A2 | HETEROCYCLIC COMPOUNDS FOR TREATING HEPATITIS C VIRUS | ANADYS PHARMACEUTICALS, INC. (US) | 2004-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050075375-A1 | Heterocyclic compounds for treating hepatitis C virus | HAVCR2, HCCS, LIPC | CASP3 330/4885GRM5 4040/4885CHUK 525/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.